GGrantIndex
Sort

15,842 grants matching pancreatic cancer

Dim light at night alters pancreatic cell signaling and predisposes to pancreatic adenocarcinoma

$167,475
Souhad Chbeir · Ohio State University · R21 · FY2017 · CA

Development of New Therapeutics for Pancreatic Cancer Management

$167,475
Richard Joseph Pietras · University Of California Los Angeles · R21 · FY2013 · CA

Identifying new drug targets to block K-Ras/Raf in pancreatic cancer.

$167,475
Philip J.s. Stork · Oregon Health & Science University · R21 · FY2016 · CA

n-3 Fatty Acid &Host Responses to Oral Infection

$167,474
University Of Kentucky · R21 · FY2002 · DE

Core D: Administrative Core

$167,454
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2020 · CA

AP 4. Drug Screening and Pharmacology

$167,400
Eric W Schmidt · University Of Utah · U19 · FY2016 · TW

Selective Targeting of MEK and AKt in Lymphoma and Myeloma Apoptosis

$167,400
Gregory B Carey · University Of Maryland Baltimore · K22 · FY2008 · CA

Selective Targeting of MEK and AKt in Lymphoma and Myeloma Apoptosis

$167,400
Gregory B Carey · University Of Maryland Baltimore · K22 · FY2007 · CA

Selective Targeting of MEK and AKt in Lymphoma and Myeloma Apoptosis

$167,400
Gregory B Carey · University Of Maryland Baltimore · K22 · FY2009 · CA

SToP Cancer SPORE: Administrative Core A

$167,361
Jen Jen Yeh · Univ Of North Carolina Chapel Hill · P50 · FY2025 · CA

Core B-Modeling & Experimental Therapeutics Core

$167,327
James Wesley Horner · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA

MR-Guided Precision Thermal Therapy of Retroperitoneal Tumors

$167,297
Frank Graham Sommer · Stanford University · P01 · FY2014 · CA

TARGETED DELIVERY OF GENES TO ANGIOGENIC VASCULATURE

$167,205
University Of Texas Md Anderson Can Ctr · R01 · FY2001 · CA

A RAS-FAM83A Regulatory Loop as a Novel Therapeutic Target for Pancreatic Cancer

$167,198
Mark W Jackson · Case Western Reserve University · R21 · FY2014 · CA

B7-H3 CAR T cell-based immunotherapy combined with Losartan to counteract desmoplasia for the treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

$167,163
Soldano Ferrone · Massachusetts General Hospital · R03 · FY2021 · CA

MUC1-Targeted Nanotherapy for Pancreatic Cancer

$167,112
Jordan M Winter · Thomas Jefferson University · R21 · FY2014 · CA

Training the Next Generation of Surgeon-Scientists in Pancreatology

$167,093
Masato Yamamoto · University Of Minnesota · T32 · FY2018 · DK

P53 and KRAS Targeted Pigs: A Platform for Models of Human Cancer

$167,065
Christopher Rogers · Exemplar Genetics, Llc · R43 · FY2012 · CA

Targeting Smad3-Ski for Therapeutic Development in Pancreatic Cancer

$167,063
F. Michael Hoffmann · University Of Wisconsin-Madison · R21 · FY2008 · CA

Project 4: Model-Based Dosimetry and Imaging for PDT

$167,050
Brian William Pogue · Massachusetts General Hospital · P01 · FY2017 · CA

Development of a protein drug for pancreatic cancer treatment

$167,021
Zhi-Ren Liu · Proda Biotech, Llc · R41 · FY2017 · CA

Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC)

$167,003
Karlyn Martin · Northwestern University At Chicago · K23 · FY2022 · HL

Implementing Prevention of Venous Thromboembolism for Ambulatory Patients with Cancer (PREVenT-APC)

$166,998
Karlyn Martin · Northwestern University At Chicago · K23 · FY2023 · HL

Core D: Administrative Core

$166,987
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2019 · CA

Structural and functional investigation of the understudied HIPK1 kinase

$166,955
Natalia Jura · University Of California, San Francisco · R03 · FY2020 · TR